Name: Abacavir
Brand: Selleck Chemicals
SKU: S5215
Availability: InStock
Rating: 5 (12 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease
Other Reverse Transcriptase Inhibitors	Dapivirine (TMC120) Fangchinoline 3'-Fluoro-3'-deoxythymidine (Alovudine) Salicylanilide Bifendate Ulonivirine Islatravir Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride

Solubility

In vitro
Batch:

DMSO : 57 mg/mL (199.07 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 57 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.85mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 57 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.41mg/ml (1.43mM)	Taking the 1 mL working solution as an example, add 50 μL of 8.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	286.33	Formula	C₁₄H₁₈N₆O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	136470-78-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	1592U89			SMILES	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Reverse transcriptase
In vitro	Abacavir (ABC) exhibits potent in vitro antiviral activity against wild-type HIV-1 (IC50 4.0 μM, MT-4 cells). This compound induces chromosomal DSBs and thereby kills ATL cells but not non-HTLV-1-infected cells. Once it is incorporated into the cells, it is phosphorylated in a unique stepwise anabolism to be converted to the triphosphated guanine analog carbovir (CBV) and then incorporated into host chromosomal DNA by replicative DNA polymerases, leading to premature termination of DNA replication, collapse of the replication fork, and DSB formation. This chemical induces S/G2-phase arrest and apoptosis in ED-40515(−) cells, but not in Jurkat cells.
In vivo	Abacavir efficiently inhibits the growth of ATL cell xenografts in NOD/SCID mice. In adults, this compound is rapidly absorbed after oral administration, with peak concentrations occurring 0.63-1 hour after dosing. The absolute bioavailability of abacavir is approximately 83%. Its pharmacokinetics are linear and doseproportional over the range of 300-1200 mg/day. The apparent volume of distribution after intravenous administration is approximately 0.86 ± 0.15 L/kg, suggesting that it is distributed to extravascular spaces. Binding to plasma proteins is about 50% and is independent of the plasma abacavir concentration. This chemical is extensively metabolized by the liver; less than 2% is excreted as unchanged drug in the urine. It is primarily metabolized via two pathways, uridine diphosphate glucuronyltransferase and alcohol dehydrogenase, resulting in the inactive glucuronide metabolite and the inactive carboxylate metabolite. The terminal elimination half-life is approximately 1.5 hours. The antiviral effect is due to its intracellular anabolite, carbovirtriphosphate (CBV-TP). This compound is not significantly metabolized by cytochrome P450 (CYP) enzymes, nor does it inhibit these enzymes.
References	[1] https://pubmed.ncbi.nlm.nih.gov/16305515/ [2] https://pubmed.ncbi.nlm.nih.gov/26601161/ [3] https://pubmed.ncbi.nlm.nih.gov/18479171/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-28)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07792096	NOT_YET_RECRUITING	HIV Infection	University College, London	2026-11	PHASE3
NCT06428045	RECRUITING	High Grade Glioma	University of Miami	2025-04-15	PHASE1
NCT06356740	NOT_YET_RECRUITING	Systemic Lupus Erythematosus	Hospices Civils de Lyon	2024-09-01	PHASE2
NCT05193994	TERMINATED	Amyotrophic Lateral Sclerosis	Macquarie University, Australia	2022-02-24	PHASE3
NCT06658977	TERMINATED	Amyotrophic Lateral Sclerosis; ALS	Macquarie University, Australia	2024-11-15	PHASE3
NCT04731103	COMPLETED	Aicardi-Goutières Syndrome	University of Edinburgh	2022-08-24	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Abacavir Reverse Transcriptase inhibitor

Chemical Structure

Molecular Weight: 286.33